Trials / Completed
CompletedNCT00987935
A Phase I / II Trial of Nintedanib in Asian Hepatocellular Carcinoma Patients
A Multicenter, Open Label, Phase I/Randomized II Study to Evaluate Safety, Pharmacokinetics and Efficacy of BIBF 1120 in Comparison With Sorafenib for Advanced Hepatocellular Carcinoma Patients in Asia.
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Boehringer Ingelheim · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is to evaluate the safety, appropriate dose, and efficacy of BIBF 1120 in liver cancer patients
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib | 400 mg twice daily |
| DRUG | BIBF 1120 | Twice daily |
Timeline
- Start date
- 2009-10-01
- Primary completion
- 2014-07-01
- Completion
- 2016-01-01
- First posted
- 2009-10-01
- Last updated
- 2016-03-10
- Results posted
- 2015-08-27
Locations
16 sites across 2 countries: South Korea, Taiwan
Source: ClinicalTrials.gov record NCT00987935. Inclusion in this directory is not an endorsement.